Skip to main content
NYSE:EVH

Evolent Health Competitors

$18.89
+0.42 (+2.27 %)
(As of 05/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$18.30
$19.21
50-Day Range
$18.43
$21.78
52-Week Range
$5.22
$22.35
Volume450,814 shs
Average Volume565,857 shs
Market Capitalization$1.63 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.4

Competitors

Evolent Health (NYSE:EVH) Vs. SMAR, CDK, ANGI, COHR, LFUS, and UPST

Should you be buying EVH stock or one of its competitors? Companies in the sector of "computer and technology" are considered alternatives and competitors to Evolent Health, including Smartsheet (SMAR), CDK Global (CDK), Angi (ANGI), Coherent (COHR), Littelfuse (LFUS), and Upstart (UPST).

Evolent Health (NYSE:EVH) and Smartsheet (NYSE:SMAR) are both computer and technology companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, valuation, analyst recommendations and earnings.

Valuation & Earnings

This table compares Evolent Health and Smartsheet's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evolent Health$846.38 million1.92$-301,970,000.00($0.91)-20.76
Smartsheet$270.88 million23.89$-95,940,000.00($0.82)-63.61

Smartsheet has lower revenue, but higher earnings than Evolent Health. Smartsheet is trading at a lower price-to-earnings ratio than Evolent Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Evolent Health and Smartsheet's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evolent Health-52.35%-4.40%-2.41%
Smartsheet-32.32%-21.98%-14.14%

Institutional and Insider Ownership

93.2% of Evolent Health shares are held by institutional investors. Comparatively, 94.6% of Smartsheet shares are held by institutional investors. 5.0% of Evolent Health shares are held by company insiders. Comparatively, 10.2% of Smartsheet shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Evolent Health has a beta of 2.4, suggesting that its share price is 140% more volatile than the S&P 500. Comparatively, Smartsheet has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Evolent Health and Smartsheet, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evolent Health03702.70
Smartsheet05902.64

Evolent Health currently has a consensus target price of $18.20, indicating a potential downside of 3.65%. Smartsheet has a consensus target price of $74.6250, indicating a potential upside of 43.07%. Given Smartsheet's higher possible upside, analysts clearly believe Smartsheet is more favorable than Evolent Health.

Summary

Smartsheet beats Evolent Health on 8 of the 14 factors compared between the two stocks.

Evolent Health (NYSE:EVH) and CDK Global (NASDAQ:CDK) are both computer and technology companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, valuation, analyst recommendations and earnings.

Valuation & Earnings

This table compares Evolent Health and CDK Global's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evolent Health$846.38 million1.92$-301,970,000.00($0.91)-20.76
CDK Global$1.96 billion3.24$207.50 million$3.0517.11

CDK Global has higher revenue and earnings than Evolent Health. Evolent Health is trading at a lower price-to-earnings ratio than CDK Global, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Evolent Health and CDK Global's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evolent Health-52.35%-4.40%-2.41%
CDK Global9.25%-62.84%12.62%

Institutional and Insider Ownership

93.2% of Evolent Health shares are held by institutional investors. Comparatively, 82.2% of CDK Global shares are held by institutional investors. 5.0% of Evolent Health shares are held by company insiders. Comparatively, 0.5% of CDK Global shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Evolent Health has a beta of 2.4, suggesting that its share price is 140% more volatile than the S&P 500. Comparatively, CDK Global has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Evolent Health and CDK Global, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evolent Health03702.70
CDK Global00303.00

Evolent Health currently has a consensus target price of $18.20, indicating a potential downside of 3.65%. CDK Global has a consensus target price of $64.75, indicating a potential upside of 24.09%. Given CDK Global's stronger consensus rating and higher possible upside, analysts clearly believe CDK Global is more favorable than Evolent Health.

Summary

CDK Global beats Evolent Health on 9 of the 14 factors compared between the two stocks.

Evolent Health (NYSE:EVH) and Angi (NASDAQ:ANGI) are both computer and technology companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, valuation, analyst recommendations and earnings.

Valuation & Earnings

This table compares Evolent Health and Angi's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evolent Health$846.38 million1.92$-301,970,000.00($0.91)-20.76
Angi$1.33 billion4.77$34.83 million$0.07180.86

Angi has higher revenue and earnings than Evolent Health. Evolent Health is trading at a lower price-to-earnings ratio than Angi, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Evolent Health and Angi's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evolent Health-52.35%-4.40%-2.41%
Angi0.56%0.62%0.40%

Institutional and Insider Ownership

93.2% of Evolent Health shares are held by institutional investors. Comparatively, 13.3% of Angi shares are held by institutional investors. 5.0% of Evolent Health shares are held by company insiders. Comparatively, 17.4% of Angi shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Evolent Health has a beta of 2.4, suggesting that its share price is 140% more volatile than the S&P 500. Comparatively, Angi has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Evolent Health and Angi, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evolent Health03702.70
Angi031002.77

Evolent Health currently has a consensus target price of $18.20, indicating a potential downside of 3.65%. Angi has a consensus target price of $16.7538, indicating a potential upside of 32.34%. Given Angi's stronger consensus rating and higher possible upside, analysts clearly believe Angi is more favorable than Evolent Health.

Summary

Angi beats Evolent Health on 12 of the 14 factors compared between the two stocks.

Evolent Health (NYSE:EVH) and Coherent (NASDAQ:COHR) are both computer and technology companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, valuation, analyst recommendations and earnings.

Valuation & Earnings

This table compares Evolent Health and Coherent's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evolent Health$846.38 million1.92$-301,970,000.00($0.91)-20.76
Coherent$1.23 billion5.09$-414,140,000.00$1.44177.66

Evolent Health has higher earnings, but lower revenue than Coherent. Evolent Health is trading at a lower price-to-earnings ratio than Coherent, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Evolent Health and Coherent's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evolent Health-52.35%-4.40%-2.41%
Coherent-33.70%3.41%1.81%

Institutional and Insider Ownership

93.2% of Evolent Health shares are held by institutional investors. Comparatively, 91.8% of Coherent shares are held by institutional investors. 5.0% of Evolent Health shares are held by company insiders. Comparatively, 0.6% of Coherent shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

Evolent Health has a beta of 2.4, suggesting that its share price is 140% more volatile than the S&P 500. Comparatively, Coherent has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Evolent Health and Coherent, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evolent Health03702.70
Coherent07202.22

Evolent Health currently has a consensus target price of $18.20, indicating a potential downside of 3.65%. Coherent has a consensus target price of $172.1429, indicating a potential downside of 32.71%. Given Evolent Health's stronger consensus rating and higher possible upside, analysts clearly believe Evolent Health is more favorable than Coherent.

Summary

Evolent Health beats Coherent on 8 of the 14 factors compared between the two stocks.

Evolent Health (NYSE:EVH) and Littelfuse (NASDAQ:LFUS) are both computer and technology companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, valuation, analyst recommendations and earnings.

Institutional and Insider Ownership

93.2% of Evolent Health shares are held by institutional investors. Comparatively, 94.2% of Littelfuse shares are held by institutional investors. 5.0% of Evolent Health shares are held by company insiders. Comparatively, 3.2% of Littelfuse shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Evolent Health and Littelfuse's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evolent Health$846.38 million1.92$-301,970,000.00($0.91)-20.76
Littelfuse$1.50 billion4.14$139.08 million$6.8237.15

Littelfuse has higher revenue and earnings than Evolent Health. Evolent Health is trading at a lower price-to-earnings ratio than Littelfuse, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for Evolent Health and Littelfuse, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Evolent Health03702.70
Littelfuse02202.50

Evolent Health currently has a consensus target price of $18.20, indicating a potential downside of 3.65%. Littelfuse has a consensus target price of $253.3333, indicating a potential downside of 0.01%. Given Littelfuse's higher possible upside, analysts clearly believe Littelfuse is more favorable than Evolent Health.

Volatility & Risk

Evolent Health has a beta of 2.4, suggesting that its share price is 140% more volatile than the S&P 500. Comparatively, Littelfuse has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500.

Profitability

This table compares Evolent Health and Littelfuse's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Evolent Health-52.35%-4.40%-2.41%
Littelfuse6.77%8.76%5.01%

Summary

Littelfuse beats Evolent Health on 10 of the 14 factors compared between the two stocks.

Upstart (NASDAQ:UPST) and Evolent Health (NYSE:EVH) are both computer and technology companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, dividends, profitability and analyst recommendations.

Insider & Institutional Ownership

93.2% of Evolent Health shares are held by institutional investors. 5.0% of Evolent Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Upstart and Evolent Health's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
UpstartN/AN/AN/AN/AN/A
Evolent Health$846.38 million1.92$-301,970,000.00($0.91)-20.76

Upstart has higher earnings, but lower revenue than Evolent Health.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Upstart and Evolent Health, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Upstart04402.50
Evolent Health03702.70

Upstart presently has a consensus price target of $98.3750, indicating a potential upside of 17.04%. Evolent Health has a consensus price target of $18.20, indicating a potential downside of 3.65%. Given Upstart's higher possible upside, equities research analysts plainly believe Upstart is more favorable than Evolent Health.

Profitability

This table compares Upstart and Evolent Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
UpstartN/AN/AN/A
Evolent Health-52.35%-4.40%-2.41%

Summary

Evolent Health beats Upstart on 5 of the 9 factors compared between the two stocks.


Evolent Health Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Smartsheet logo
SMAR
Smartsheet
1.8$52.16+2.8%$6.47 billion$270.88 million-54.91
CDK Global logo
CDK
CDK Global
2.0$52.18+1.2%$6.35 billion$1.96 billion35.26Earnings Announcement
Angi logo
ANGI
Angi
1.0$12.66+4.7%$6.33 billion$1.33 billion1,267.27Analyst Upgrade
Analyst Revision
Coherent logo
COHR
Coherent
1.5$255.83+0.5%$6.26 billion$1.23 billion-14.88Earnings Announcement
Littelfuse logo
LFUS
Littelfuse
1.7$253.37+2.8%$6.22 billion$1.50 billion66.68Insider Selling
Upstart logo
UPST
Upstart
1.4$84.05+9.2%$6.21 billionN/A0.00Earnings Announcement
Analyst Report
High Trading Volume
News Coverage
Gap Up
SYNNEX logo
SNX
SYNNEX
1.9$118.50+2.9%$6.14 billion$24.68 billion11.62Insider Selling
NCR logo
NCR
NCR
1.7$46.69+3.3%$6.11 billion$6.92 billion14.64Analyst Report
CACI International logo
CACI
CACI International
2.0$258.86+1.9%$6.10 billion$5.72 billion19.01Analyst Report
BWX Technologies logo
BWXT
BWX Technologies
2.0$63.59+0.4%$6.05 billion$1.89 billion22.23
Lattice Semiconductor logo
LSCC
Lattice Semiconductor
1.4$43.96+0.9%$6.00 billion$404.09 million133.21Insider Selling
Gap Up
Nutanix logo
NTNX
Nutanix
1.8$28.71+6.8%$5.86 billion$1.31 billion-6.24Analyst Upgrade
High Trading Volume
BlackLine logo
BL
BlackLine
1.8$100.14+2.2%$5.81 billion$288.98 million-145.13Earnings Announcement
Analyst Upgrade
Insider Selling
PLDT logo
PHI
PLDT
1.5$26.24+0.2%$5.67 billion$3.32 billion11.07Earnings Announcement
TIM logo
TIMB
TIM
2.2$11.53+1.6%$5.58 billion$4.22 billion13.56Upcoming Earnings
Analyst Report
Silicon Laboratories logo
SLAB
Silicon Laboratories
2.1$123.38+0.4%$5.52 billion$837.55 million411.27
J2 Global logo
JCOM
J2 Global
1.4$122.05+0.8%$5.51 billion$1.37 billion27.55Earnings Announcement
Analyst Report
Appian logo
APPN
Appian
1.4$77.49+6.7%$5.48 billion$260.35 million-140.89Analyst Downgrade
News Coverage
WESCO International logo
WCC
WESCO International
1.6$107.92+5.4%$5.41 billion$8.36 billion39.10Earnings Announcement
Analyst Report
Insider Selling
Analyst Revision
News Coverage
ASGN logo
ASGN
ASGN
1.5$100.85+1.2%$5.37 billion$3.92 billion29.06
Scientific Games logo
SGMS
Scientific Games
1.3$55.68+3.9%$5.35 billion$3.40 billion-10.07Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Grubhub logo
GRUB
Grubhub
1.4$56.74+2.8%$5.30 billion$1.31 billion-45.39Analyst Upgrade
COMP
Compass
1.8$13.66+5.8%$5.29 billionN/A0.00Analyst Report
High Trading Volume
Quiet Period Expiration
Gap Up
nVent Electric logo
NVT
nVent Electric
2.1$31.26+2.2%$5.24 billion$2.20 billion-107.79Analyst Report
Insider Selling
Lightspeed POS logo
LSPD
Lightspeed POS
1.7$55.70+3.6%$5.20 billion$120.64 million-68.76Upcoming Earnings
News Coverage
Lightspeed POS logo
LSPD
Lightspeed POS
1.6$55.70+3.6%$5.20 billion$120.64 million-68.76
Q2 logo
QTWO
Q2
1.6$91.39+0.7%$5.15 billion$315.48 million-40.08Analyst Upgrade
Insider Selling
Gap Up
Lumentum logo
LITE
Lumentum
2.2$67.43+1.2%$5.10 billion$1.68 billion33.88Earnings Announcement
Analyst Downgrade
High Trading Volume
News Coverage
Science Applications International logo
SAIC
Science Applications International
2.8$87.73+0.4%$5.09 billion$6.38 billion24.92Analyst Report
News Coverage
National Instruments logo
NATI
National Instruments
1.5$38.59+0.7%$5.08 billion$1.35 billion25.73
Digital Turbine logo
APPS
Digital Turbine
1.8$56.77+2.5%$5.08 billion$138.71 million189.24Analyst Report
Gap Up
SolarWinds logo
SWI
SolarWinds
1.3$16.02+0.6%$5.06 billion$932.53 million133.51Analyst Downgrade
Alteryx logo
AYX
Alteryx
1.7$74.91+4.4%$5.01 billion$417.91 million-277.44Analyst Report
Endava logo
DAVA
Endava
1.2$93.16+1.7%$4.94 billion$435.42 million310.53Upcoming Earnings
High Trading Volume
News Coverage
C3.ai logo
AI
C3.ai
1.0$48.89+5.5%$4.93 billionN/A0.00
Iridium Communications logo
IRDM
Iridium Communications
1.1$36.56+3.5%$4.88 billion$560.44 million-30.98
The Descartes Systems Group logo
DSGX
The Descartes Systems Group
1.7$57.66+0.5%$4.87 billion$325.79 million108.79News Coverage
Pure Storage logo
PSTG
Pure Storage
1.9$17.18+0.9%$4.82 billion$1.64 billion-19.30Analyst Upgrade
News Coverage
Gap Up
Upwork logo
UPWK
Upwork
1.4$37.99+0.5%$4.79 billion$300.56 million-151.96Analyst Downgrade
Perspecta logo
PRSP
Perspecta
0.9$29.34+0.0%$4.73 billion$4.50 billion-6.55Upcoming Earnings
nCino logo
NCNO
nCino
1.2$49.76+2.6%$4.70 billionN/A0.00High Trading Volume
Gap Up
Varonis Systems logo
VRNS
Varonis Systems
1.7$44.17+2.4%$4.69 billion$254.19 million-15.61Analyst Report
MicroStrategy logo
MSTR
MicroStrategy
1.0$488.08+11.0%$4.68 billion$486.33 million4,067.33Analyst Report
Gap Down
ACI Worldwide logo
ACIW
ACI Worldwide
1.1$39.50+2.3%$4.67 billion$1.26 billion77.45Insider Selling
News Coverage
Watts Water Technologies logo
WTS
Watts Water Technologies
1.7$138.58+3.8%$4.66 billion$1.60 billion40.76Insider Selling
Analyst Revision
FireEye logo
FEYE
FireEye
1.2$19.51+1.5%$4.65 billion$889.15 million-19.71Insider Selling
Novanta logo
NOVT
Novanta
1.5$131.04+1.9%$4.64 billion$626.10 million112.97Earnings Announcement
Duck Creek Technologies logo
DCT
Duck Creek Technologies
1.6$35.22+4.1%$4.63 billion$211.67 million-320.18
Inovalon logo
INOV
Inovalon
1.2$29.65+0.9%$4.62 billion$642.41 million741.44
DV
DoubleVerify
0.0$29.71+12.9%$4.61 billionN/A0.00News Coverage
This page was last updated on 5/13/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.